News
CSBR
--
0.00%
--
Champions Oncology And BGI Americas Announce Partnership To Provide Mass Spectrometry Proteomics, Metabolomics, And Multi-Omic Data Analysis Solutions
Champions Oncology (NASDAQ:CSBR), a technology-enabled research organization announced today that they have entered into a strategic partnership with BGI Americas. Through this partnership, BGI will now have access
Benzinga · 5d ago
Champions Oncology and BGI Americas Announce a Strategic Partnership to Provide Mass Spectrometry Proteomics, Metabolomics, and Multi-Omic Data Analysis Solutions
HACKENSACK, NJ / ACCESSWIRE / June 15, 2021 / Champions Oncology (NASDAQ:CSBR), a technology-enabled research organization announced today that they have entered into a strategic partnership with BGI Americas.Through this partnership, BGI will now have acc...
ACCESSWIRE · 5d ago
4 Promising Oncology Stocks to Consider Adding to Your Portfolio
StockNews.com · 06/11 16:30
3 Biotech Stocks Wall Street Predicts Will Rally By 45% or More
StockNews.com · 05/28 15:04
Global Humanized Mouse and Rat Model Market size estimate, share 2021, expansion plans, industry update, gross margin, revenue forecast 2025
May 10, 2021 (The Expresswire) -- Global "Humanized Mouse and Rat Model Market" covers historical and forecast data from like demand, application details and...
The Express Wire · 05/10 10:03
Patient Derived Xenograft or PDX Models Market Share, Size, Global Development ,Growth Status, Sales Revenue, Emerging Technologies, Key Players Analysis, Opportunity Assessment and Industry Expansion Strategies 2025
May 05, 2021 (The Expresswire) -- Global Patient Derived Xenograft or PDX Models Market Research report provides detailed analysis of global market size,...
The Express Wire · 05/05 07:14
Roubaix Capital, LLC Buys Immersion Corp, Despegar. ...
GuruFocus News · 04/29 21:38
Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 04/29 07:31
Patient Derived Xenograft Models Market Size, Share, Trends, Analysis and Forecast 2027
Apr 28, 2021 (Market Insight Reports) -- The Global Patient Derived Xenograft Models Market is estimated to value over USD 240 million by 2027 end and...
Market Insight Reports · 04/28 11:23
Humanized Mouse and Rat Model Industry Share, Global Industry Growth, Historical Analysis, Size, Trends, Emerging Factors, Demands, Key Players, Emerging Technologies and Potential of Industry Till 2026
Apr 27, 2021 (The Expresswire) -- Global Humanized Mouse and Rat Model Market Research Report has In-Depth Collective analysis of different factors that...
The Express Wire · 04/27 09:58
The global Patient-Derived Xenograft/PDX models market size is projected to reach USD 299 million by 2026 from USD 140 million in 2021, at a CAGR of 16.4%
New York, April 23, Apr 23, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, April 23, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the...
GlobeNewswire · 04/23 11:26
PDX Model Market to Reach USD 299 million by 2026 | Key Players are JSR Corporation (Japan), WuXi AppTec (China)
Apr 20, 2021 (AB Digital via COMTEX) -- This study involved four major activities in estimating the current size of the PDX model market. Exhaustive...
ABNewswire · 04/20 22:35
Global Cell-based Humanized Mouse Models Market Outlook, Industry Analysis and Prospect 2021-2026
Apr 16, 2021 (Heraldkeepers) -- The Cell-based Humanized Mouse Models market report provides a detailed analysis of global market size, regional and...
Heraldkeepers · 04/16 16:02
Champions Oncology, Inc. (CSBR) Upgraded to Buy: What Does It Mean for the Stock?
Zacks.com · 04/16 05:05
Humanized Mouse Model Market Size, Share, Trend, Growth Rate, Value & Volume By Production, Types, Segmentation, Scope, Application, Opportunity and Forecast By 2021 - 2024
Apr 14, 2021 (The Expresswire) -- Global "Humanized Mouse Model Market" Report 2021 is a comprehensive, professional report provides a detailed overview of...
The Express Wire · 04/14 06:18
Global Patient Derived Xenograft Market Statistics, Cagr, Outlook, And Covid-19 Impact 2021 - 2023
Apr 05, 2021 (Heraldkeepers) -- This report researches the worldwide Patient Derived Xenograft Models market size (value) in key regions like United States,...
Heraldkeepers · 04/05 13:45
Global Patient Derived Xenograft or PDX Models Industry Market Outlook, Industry Analysis and Prospect 2020
Mar 30, 2021 (Heraldkeepers) -- Patients – Derived xenografts (PDX) are models of cancer in which tumors from patients with the above tissues or cells are...
Heraldkeepers · 03/30 07:06
COVID-19 Business Impact: Patient Derived Xenograft PDX Models Market Hierarchy of Needs -Moving from Pandemic Risk Management to Organizational Agility During 2025
Mar 23, 2021 (AmericaNewsHour) -- The global Patient Derived Xenograft/PDX Models Market was valued at USD 66.9 million in 2016 and is projected to reach USD...
AmericaNewsHour · 03/23 06:35
The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 16)
Benzinga · 03/17 11:43
Strength Seen in Champions Oncology, Inc. (CSBR): Can Its 15.3% Jump Turn into More Strength?
Champions Oncology, Inc. (CSBR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks · 03/16 15:52
Webull provides a variety of real-time CSBR stock news. You can receive the latest news about Champions through multiple platforms. This information may help you make smarter investment decisions.
About CSBR
Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology, in conjunction with related services, to offer solutions for two consumer groups: Translational Oncology Solutions (TOS) and Personalized Oncology Solutions (POS). The Company’s TOS business offers a technology platform to pharmaceutical and biotechnology companies using TumorGraft studies. POS assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The Company subsidiaries include Champions Oncology (Israel) and Limited and Champions Biotechnology U.K., Limited.